Evgen makes second move for AIM listing

Evgen Pharma is making a fresh bid to become a public company.

The Liverpool-based company, which is focused on treatments for cancer, strokes and Multiple Schlerosis, is looking to join the junior market AIM later this month and is looking to raise approximately £5m through a shares placing.

Its core technology Sulforadex is a patent-protected method of stabilising a synthetic version of sulforaphane, which is a naturally occurring, known anti-cancer agent derived from broccoli and other brassica vegetables.

Chief executive Dr Stephen Franklin said: “The anti-cancer and anti-inflammatory properties of sulforaphane are well documented and are supported by a wealth of published peer-reviewed scientific papers. Our exciting Sulforadex technology stabilises the molecule and unlocks its commercial potential, representing a major breakthrough as a potential therapy in cancer, neurology and other disease areas.

“We intend to advance our programmes in breast cancer, stroke and multiple sclerosis through this IPO on the AIM market of the London Stock Exchange.”

 

See article in full at BusinessDesk.com

Important information

This information is of a general nature and does not constitute an offer to provide services.

The opinions and conclusions given here are those of Seneca Partners and are subject to change without notice.

The value of investments and/or any income arising from them may fluctuate.

Past performance is not necessarily a guide to future performance.

Important notice

The products and services shown on this website place capital at risk. Investors may receive less in returns than they have invested. Investments may not allow for capital to be withdrawn on demand. If an investment provides tax relief then this relief is subject to change and is dependant on personal circumstances. Any reference to past performance or forecasted performance is not a reliable indicator of future performance.

Seneca Partners recommends that any investor seeks specialised financial and/or tax advice before investing. Seneca Partners does not provide advice and the information on this website, including but not limited to news, should not be construed as such.

Please confirm that you understand this warning and wish to proceed.